Oxaliplatin

Catalog No.S1224 Synonyms: L-OHP

Oxaliplatin Chemical Structure

Molecular Weight(MW): 397.29

Oxaliplatin inhibits DNA synthesis by conforming DNA adducts in RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2, and HT-144 cells.

Size Price Stock Quantity  
USD 70 In stock
USD 120 In stock
USD 210 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 22 Publications

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Biological Activity

Description Oxaliplatin inhibits DNA synthesis by conforming DNA adducts in RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2, and HT-144 cells.
Targets
DNA synthesis [1]
(RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2, HT-144 cells)
In vitro

The main mechanism of action of Oxaliplatin is mediated through the formation of DNA–adducts. Oxaliplatin induces primary and secondary DNA lesions that lead to cell apoptosis. [1] Oxaliplatin is active against human melanoma cell lines C32 and G361 with IC50 of 0.98 mM and 0.14 mM, respectively. [2] Oxaliplatin effectively inhibits bladder carcinoma cell lines RT4 and TCCSUP, ovarian carcinoma cell line A2780, colon carcinoma cell line HT-29, glioblastoma cell lines U-373MG and U-87MG, and melanoma cell lines SK-MEL-2 and HT-144 with IC50 of 11 μM, 15 μM, 0.17 μM, 0.97 μM, 2.95 μM, 17.6 μM, 30.9 μM and 7.85 μM, respectively. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HKESC-2 NV73fpdvS3m2b4TvfIlkcXS7IFHzd4F6 NEjBSpEx6oDVMU[wxsDPxE1? MW[0POKhcA>? NIDEfVZKSzVyPUWuPOKhyrIEoECuOUDPxE1? NFnobIYzPjR5NE[5Ny=>
CaES-17 NWTZR4xuS3m2b4TvfIlkcXS7IFHzd4F6 M1W1RVDjiJNzNkFCpO69VQ>? M{LKcFQ5yqCq MoLOTWM2OD13LkZCpOKyyqByLkKg{txO NX;kO|cxOjZ2N{S2PVM>
SW480 NIDudoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3qxXlQ5KGkEoB?= M2DPdWlEPTB;MT64O{DPxE1? M1jnVlI3OjZ7N{W5
HCT116 NX;VXpRWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;6OFghcMLi M{jnTGlEPTB;MUGuPFYh|ryP M1Tqb|I3OjZ7N{W5
LoVo MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1yyU|Q5KGkEoB?= NILp[IdKSzVyPUm0Mlg{KM7:TR?= NYm5U4V4OjZ{Nkm3OVk>
SK-BR-3 M{LPXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\4S41KSzVyPUOxMlAhyrFiMD6xJO69VQ>? NXr5TIRmOjZ{MUG1PVE>
MCF-7 M2DaWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfjN5JKSzVyPUG1MlQhyrFiMD6zJO69VQ>? MkTsNlYzOTF3OUG=
MDA-MB-231 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTJ|LkGgxtEhOC5zIN88US=> M2LWcFI3OjFzNUmx
HCT116 p53+/+ MYPGeY5kfGmxbjDBd5NigQ>? NXfYWoFROS93IN88US=> MoX1NlQwPDhiaB?= MVnpcoR2[2W|IITyZY5{[3KrcITpc45idCC{ZYDy[ZN{cW:wIH;mJGRWXC2Q Mn3ZNlYzODh3MkO=
LoVo  NULTO4w3TnWwY4Tpc44hSXO|YYm= NIXofpkyNzVizszN Mnz2NlQwPDhiaB?= MWLpcoR2[2W|IITyZY5{[3KrcITpc45idCC{ZYDy[ZN{cW:wIH;mJGRWXC2Q M4f1W|I3OjB6NUKz
SNU-398 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnrGTWM2OD14LkZCpOKyyqBzLkGg{txO Mn;0NlYyPjB2Mkm=
Hep-G2 MkDZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzGe4ZKSzVyPUGzMlHDqMLzwrCxMlYh|ryP MlTTNlYyPjB2Mkm=
SNU-475 NFy2dYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\OTWM2OO,:nkOwJO69VQ>? M{HNN|I3OTZyNEK5
SNU-387 NV35eHIzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHr[4dEUUN3ME2yOeKhyrIEoEKuO{DPxE1? M1y2UFI3OTZyNEK5
HT29 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPMTWM2OD1yLki4xsDDucLiMD6yJO69VQ>? M4TMSVI3OTR6NUm2
HCT116 NGjsN2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7JPYlKSzVyPUCuOFHDqMLzwrCwMlAzKM7:TR?= MWmyOlE1QDV7Nh?=
PA-1 M1nnVWNmdGxiVnnhZoltcXS7IFHzd4F6 NVL1enRnOC1{MDFOwG0> M4PxVFI1NzR6IHi= M4DlR4lvcGmkaYTzJINmdGxidnnhZoltcXS7IHnuJIJwfGhidHnt[UBidmRiZH;z[UBl\XCnbnTlcpQhdWGwbnXy M37NfVI3OTN6Nkex
OVCAR-5 NXHDTmtMS2WubDDWbYFjcWyrdImgRZN{[Xl? NU\ZTVVEOC14MDFOwG0> M3f1cVI1NzR6L{eyJIg> NVTLO3RscW6qaXLpeJMh[2WubDD2bYFjcWyrdImgbY4h[m:2aDD0bY1mKGGwZDDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> NWjoW|VoOjZzM{i2O|E>
SK-OV-3 MXjD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MojINE0yODBizszN MWWyOE81QC95MjDo NYHXNnRPcW6qaXLpeJMh[2WubDD2bYFjcWyrdImgbY4h[m:2aDD0bY1mKGGwZDDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> MofCNlYyOzh4N{G=
PA-1 M3nSdmZ2dmO2aX;uJGF{e2G7 M1;3Z|ExKM7:TdMg MUGyOIg> MlnleJJq\2encnXzJJRp\SCycn;keYN1cW:wIH;mJJR6eGViSTDJSm5{KGGwZDDjbIVud2urbnXz MnraNlYyOzh4N{G=
OVCAR-5 MVHGeY5kfGmxbjDBd5NigQ>? Ml\0N|Ah|ryP NGLqbos1QGh? NHSyUnR1emmpZ3Xy[ZMhfGinIIDyc4R2[3Srb36gc4YhfHmyZTDJJGlHVnNiYX7kJINp\W2xa3nu[ZM> NFTK[oEzPjF|OE[3NS=>
SK-OV-3 M2DCeGZ2dmO2aX;uJGF{e2G7 NIraVVk2OCEQvF2= NXLCN5VFQTZiaB?= MV\0dolo\2W{ZYOgeIhmKHC{b3T1Z5Rqd25ib3[geJlx\SCLIFnGUpMh[W6mIHPo[Y1wc2mwZYO= MknaNlYyOzh4N{G=
PA-1 Mnn1SpVv[3Srb36gRZN{[Xl? MmrzNVAh|ryPwrC= Ml61OFhp MmPaeZAuemWpdXzheIV{KHSqZTDzeJJme3NibHnnZY5leyCob4KgUmsh[2WubD3hZ5RqfmG2aX7nJJJm[2WydH;yd{BidmRiVGLBTWwhemWlZYD0c5J{ M3rwZlI3OTN6Nkex
OVCAR-5 MYPGeY5kfGmxbjDBd5NigQ>? NYTrXYh[OzBizszN MmPLOFhp MVn1dE1z\We3bHH0[ZMhfGinIIP0doV{eyCuaXfhcoR{KG[xcjDOT{Bk\WyuLXHjeIl3[XSrbnegdoVk\XC2b4LzJIFv\CCWUlHJUEBz\WOncITvdpM> MlruNlYyOzh4N{G=
SK-OV-3 NITMNnZHfW6ldHnvckBCe3OjeR?= NF7qfWI2OCEQvF2= MljiPVYhcA>? NG[zWlh2eC2{ZXf1cIF1\XNidHjlJJN1emW|czDsbYdidmS|IH\vdkBPUyClZXzsMYFkfGm4YYTpcochemWlZYD0c5J{KGGwZDDUVmFKVCC{ZXPldJRwenN? MmXhNlYyOzh4N{G=
PA-1 M2jae2Z2dmO2aX;uJGF{e2G7 MWmxNEDPxE4EoB?= MYSyOIg> Mn63dJJwdW:2ZYOgd4Vve2m2aY\peJkhd2Zib4\hdolidiClYYLjbY5wdWFidH:gUmsh[2WubD3t[YRq[XSnZDDjfZRwdHm|aYO= M3fy[|I3OTN6Nkex
OVCAR-5 NXLHT5VSTnWwY4Tpc44hSXO|YYm= NIPyTpEzOCEQvF5CpC=> NF7rOXQzPGh? MYTwdo9ud3SnczDz[Y5{cXSrdnn0fUBw\iCxdnHybYFvKGOjcnPpco9u[SC2bzDOT{Bk\WyuLX3l[IlifGWmIHP5eI9tgXOrcx?= NWTJToJxOjZzM{i2O|E>
SK-OV-3 NF3KeJNHfW6ldHnvckBCe3OjeR?= NHK0[XY2OCEQvF5CpC=> MkX5OFghcMLi MYLwdo9ud3SnczDz[Y5{cXSrdnn0fUBw\iCxdnHybYFvKGOjcnPpco9u[SC2bzDOT{Bk\WyuLX3l[IlifGWmIHP5eI9tgXOrcx?= NUP3OmZuOjZzM{i2O|E>
CT26  NV;6[HRmTnWwY4Tpc44hSXO|YYm= M2rOVVQhdU1? MkXUOFghcMLi MVXpcoR2[2W|IHH1eI9xcGGpeR?= MYOyOlE{PzBzMh?=
CT26  NUjqenExTnWwY4Tpc44hSXO|YYm= MUm0JI1O NVfBSVNHPDhiaNMg MkfubY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIHzleoVteyCxZjDheZRweGijZ4mtdoVt[XSnZDDwdo91\Wmwczygd5VkcCCjczDMR|MuUUluIFLlZ4xqdjFiYX7kJGFVTzV? M4XxelI3OTN5MEGy
CT26  NEm4dIxE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NV\He2Q2PCCvTR?= NUHMToJCPDhiaNMg MWTk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHlidH:gOVMvOiV? MVeyOlE{PzBzMh?=
BE MnT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLuW4FvUUN3ME2zMlM{KM7:TR?= MWmyOlAzOzB6NR?=
Colo205 M4Ti[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWKyeZdpUUN3ME2zMlM{KM7:TR?= NXzRXW5DOjZyMkOwPFU>
DLD1 NGHOZ29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPCWHZTUUN3ME2yMlAyKM7:TR?= NVu3OXJNOjZyMkOwPFU>
HT29 NVO2cWpCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4riZmlEPTB;Mj62PUDPxE1? M3nDZlI3ODJ|MEi1
HCT15 M1\DVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLHTWM2OD1zLkSzJO69VQ>? MWmyOlAzOzB6NR?=
HCT116 M4fUeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{frPGlEPTB;MT6wOEDPxE1? NHHYNoMzPjB{M{C4OS=>
HCT116p53- NXfpc3ZTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLKTWM2OD1zLkC4JO69VQ>? MWmyOlAzOzB6NR?=
KM12 NYe2XG1ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTRwM{eg{txO MXyyOlAzOzB6NR?=
LoVo MoPkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7jTWM2OD1zLkKg{txO NYLuUG03OjZyMkOwPFU>
RKO NVKxWmpiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDmTWM2OD1zLkKzJO69VQ>? NXfWepJlOjZyMkOwPFU>
SW480 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfGW45XUUN3ME2yMlg3KM7:TR?= NGrmfm8zPjB{M{C4OS=>
SW620 NYTWSGlZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUDFd3lGUUN3ME2zMlY5KM7:TR?= MX2yOlAzOzB6NR?=
MC38 NVLwPW1yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLETWM2OD1{MzFOwG0hyrFiMh?= MUKyOlAxPDB6NB?=
HT29 NEDUR|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTZ|IN88UUDDuSBzOB?= M4LMdFI3ODB2MEi0
DLD-1 NWK0b4N3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTN{LkKg{txO Mki4NlYxODNyOEW=
HT-29 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTN3Lk[g{txO MUKyOlAxOzB6NR?=
SiHa NH7ZUG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEG1ZpJKSzVyPUCuPEDDuSByLkGg{txO M2fUR|I2QDBzMEC3
S3 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4nsemlEPTB;NUOuOUDDuSBzLkWg{txO NVKx[FgzOjV6MEGwNFc>
AGS MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7lTWM2OD1zMD62JO69VQ>? MlXUNlU4QDlyNUe=
MKN-45 NVL4R4pbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHz5NmRKSzVyPUG0MlAh|ryP M4r2XFI2Pzh7MEW3
TMK-1 MonES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkG0TWM2OD1{Mj62JO69VQ>? NGXYepEzPTd6OUC1Oy=>
SCM-1 NGC5W2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\LTZhIUUN3ME2xO{42KM7:TR?= MUiyOVc5QTB3Nx?=
HCT-15 MmTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnzxTWM2OD16Lk[0JO69VQ>? MkDiNlU4PjF2N{m=
DiFi NVvUOHhjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvpWYNKSzVyPUGwMlk2KM7:TR?= MY[yOVc3OTR5OR?=
DLD-1 NYO5[nR5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4P2ZmlEPTB;OD62OUDPxE1? NVzNPGlFOjV5NkG0O|k>
COLO-320DM NHS4SYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{j4R2lEPTB;NT6zPEDPxE1? NFvqNY0zPTd4MUS3PS=>
SNU-175 NEDoZ2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPVTWM2OD1zLkWxJO69VQ>? M2T0WlI2PzZzNEe5
HT-29 Ml3xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfFOHZKSzVyPUWuNlIh|ryP M4jHVlI2PzZzNEe5
SW620 MmLnSpVv[3Srb36gRZN{[Xl? NHnBeJEyOOLCidM1[{9udA>? MXKyOQKBkWh? MnTEbY5kemWjc3XzJGxEOy2LSTDhZ4N2dXWuYYTpc44h[W6mIHTlZ5Jm[XOnczDQOlIh\XiycnXzd4lwdg>? NHLEb28zPTd2OUSyNC=>
SW480 NUjk[mhVTnWwY4Tpc44hSXO|YYm= MnnGNVDjiIoEtXevcYw> Mk\NNlTjiImq NGHPVoRqdmO{ZXHz[ZMhVEN|LVnJJIFk[3WvdXzheIlwdiCjbnSg[IVkemWjc3XzJHA3OiCneIDy[ZN{cW:w MljGNlU4PDl2MkC=
SW620 MWPGeY5kfGmxbjDBd5NigQ>? NWrPNmU3OTEkgJpCuYcwdWx? MV6yOQKBkWh? NY\yNGIz\W6qYX7j[ZMh[2WubIXsZZIh[XW2b4DoZYdq[yCobIX4 NEjDOJgzPTd2OUSyNC=>
SW480 Ml7mSpVv[3Srb36gRZN{[Xl? Mnn3NVDjiIoEtXevcYw> MU[yOQKBkWh? NV35OFB{\W6qYX7j[ZMh[2WubIXsZZIh[XW2b4DoZYdq[yCobIX4 NWrKVYVlOjV5NEm0NlA>
A549 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rURWlEPTB;NT64JOKyKDBwNjFOwG0> M4DaWVI2PjJ3MkSz
A549/CDDP MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFHEbIpKSzVyPUG4MlYhyrFiMT6yJO69VQ>? NXPCUpZEOjV4MkWyOFM>
Panc-1 M1vZUWNmdGxiVnnhZoltcXS7IFHzd4F6 Mlv0NlUwPTBizszN MknPNlQwPDhiaB?= M4eyeolvcGmkaYTzJJBzd2yrZnXyZZRqd25ib3[gVGMh[2WubIOgbY4h[SC|eX7ldodqe3SrYzDtZY5v\XJiY3;tZolv\WRid3n0bEBYSQ>? NEW3UmszPTR2NEmxOC=>
MIAPaCa-2 MoHqR4VtdCCYaXHibYxqfHliQYPzZZk> M130TlI2NzVyIN88US=> M4LhOlI1NzR6IHi= MWrpcohq[mm2czDwdo9tcW[ncnH0bY9vKG:oIGDDJINmdGy|IHnuJIEhe3mwZYLnbZN1cWNibXHucoVzKGOxbXLpcoVlKHerdHigW2E> MWOyOVQ1PDlzNB?=
SW1990 M1rY[GNmdGxiVnnhZoltcXS7IFHzd4F6 MXSyOU82OCEQvF2= M1zYZ|I1NzR6IHi= MmXpbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCxZjDQR{Bk\WyuczDpckBiKHO7bnXy[4l{fGmlIH3hco5meiClb33ibY5m\CC5aYToJHdC MUOyOVQ1PDlzNB?=
HPDE NIHvWZRE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NUXuWlY3OjVxNUCg{txO NVjVc3VDOjRxNEigbC=> M2nnUolvcGmkaYTzJJBzd2yrZnXyZZRqd25ib3[gVGMh[2WubIOgbY4h[SC|eX7ldodqe3SrYzDtZY5v\XJiY3;tZolv\WRid3n0bEBYSQ>? NHTCdIszPTR2NEmxOC=>
Panc-1 M4LDSWFxd3C2b4Ppd{BCe3OjeR?= M17HclI26oDLwsXN MmP0NlQhcA>? M4\EdYlv\HWlZYOgZZBweHSxc3nzJIlvKGFic4nu[ZJocXO2aXOgcYFvdmW{IHPvcYJqdmWmIIfpeIghX0F? MUGyOVQ1PDlzNB?=
MIAPaCa-2 NI\qXIxCeG:ydH;zbZMhSXO|YYm= Mo\BNlXjiIoEtV2= M2jBVVI1KGh? NUj1NW1PcW6mdXPld{BieG:ydH;zbZMhcW5iYTDzfY5memerc4TpZ{Bu[W6wZYKgZ49u[mmwZXSge4l1cCCZQR?= MVSyOVQ1PDlzNB?=
Panc-1 NUDoZoNLTnWwY4Tpc44hSXO|YYm= NETVWFYzPeLCidM1US=> MVSyOE81QCCq NHHXWZBqdmS3Y3XzJINt\WG4YXflJI9nKFCDUmCsJINie3Cjc3WtPUwh[2G|cHHz[U05KGGwZDDjZZNx[XOnLURCpC=> MnzENlU1PDR7MUS=
MIAPaCa-2 MXzGeY5kfGmxbjDBd5NigQ>? NH61SJczPeLCidM1US=> MYmyOE81QCCq NYDjdJFqcW6mdXPld{BkdGWjdnHn[UBw\iCSQWLQMEBk[XOyYYPlMVktKGOjc4Dhd4UuQCCjbnSgZ4F{eGG|ZT2zxsA> MUOyOVQ1PDlzNB?=
SW480 MnXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vWVVczKGkEoB?= M{G3W2lEPTB;MUCuO:KyOi5{NjFCuYcwdUx? MYSyOVM3ODZ|MR?=
HCT116  MlnIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3i2SVczKGkEoB?= NYXJZVJyUUN3ME22MlI{yrFyLke1JOK2\y:vTB?= M37mVlI2OzZyNkOx
COC1 MonOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7lTHRNUUN3ME20Ok4zOMLiwsJCpFMvOTRizszN M17EN|I2OzB5NES4
SGC7901 NUfPZ4ZkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\TUYJKSzVyPUKxMlc{yqEEsdMgN{4xQCEQvF2= NYDiNGFROjV|MEe0OFg>
A549 Mlz1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37Jd2lEPTB;NUGuNFjDqMLzwrCxNE46PiEQvF2= NVS0UYF4OjV|MEe0OFg>
HepG2 MkXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXVZoJ6UUN3ME2xOE4zPMLiwsJCpFEvQDJizszN NFnkdmUzPTNyN{S0PC=>
MCF-7 MljMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH[1V2lKSzVyPUG0MlI1yqEEsdMgNU45OiEQvF2= NUjVOZgyOjV|MEe0OFg>
HCT-116 M4T3UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrGUWNKSzVyPU[uNlTDqMLzwrCyMlk4KM7:TR?= MY[yOVMxPzR2OB?=
HT-29 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRjVyIN88US=> NYi2N|B6OjV|MEe0OFg>
HEK293 NXvzfIFkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\YOm12UUN3ME24MlgzyqEEsdMgOU42QSEQvF2= M{jqTlI2OzB5NES4
HUVEC NVnmTXVlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13ENmlEPTB;MUGuN|DDqMLzwrCxMlAzKM7:TR?= NFe5Vm0zPTNyN{S0PC=>
SW480 MkDwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYixxsDPxE1? NULzeYluOC15MjDo NH\MS|ZqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJJRqdWViZHXw[Y5l\W62IH3hco5meg>? MmX2NlQ6QTd2NUG=
HT-29 NXzvd5RST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfMeVQyyqEQvF2= MXGwMVczKGh? MY\pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIITpcYUh\GWyZX7k[Y51KG2jbn7ldi=> MVSyOFk6PzR3MR?=
HCT116 Mke2SpVv[3Srb36gRZN{[Xl? M3nQfVIwPSEEtV2= M3HKblI1NzR6IHi= NGTY[Xp{fXCycnXzd4V{KHO3co\peolvKG2UTlGg[ZhxemW|c3nvci=> M2T0O|I1PzZzNEGx
SW480  NGT4VoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUO0PEBpyqB? NHLScIVKSzVyPUKwMlghfWdxbVy= NVXwUppbOjR5MkC2O|U>
SW620 NWDFN45QT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPJcZZIOTBvN{CgcYcwVA>? MnXoNlQwPDhxN{KgbC=> M1;UOIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZTDhcoQh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ NFXCOnUzPDZ2NkOwOS=>
Caco2  MlHISpVv[3Srb36gRZN{[Xl? NHH0VWM{OMLizszN M1jvfFI1KGh? MnPxSG1UVw>? MkjEbY5lfWOnczD0bIUh\XiycnXzd4lwdiCxZjDIU{0yNCCDS2KxR{wh[W6mIF7RU|E> M2j3UVI1PTV4NEG1
Caco2  NXXQU21vTnWwY4Tpc44hSXO|YYm= MnjrN{8yOC9|MDFOwG0> MUKxOkBp MUfEUXNQ M4HnWolv[3KnYYPld{B1cGVibWLORUBt\X[nbIOgc4bDqEGNUkHDNUwhVlGRMTygTG8uOSxiTWLQNkzDqGGwZF3SVFPDqGSxc3Wt[IVx\W6mZX70cJk> NIraRmozPDV3NkSxOS=>
Caco2 M3nHUGZ2dmO2aX;uJGF{e2G7 NHXLeIY{OC9zMEFCpO69VQ>? MYmxOuKhcA>? NHX6[2xFVVOR MVjhZ5RqfmG2ZYOgUpJnOg>? MUSyOFU2PjRzNR?=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
VEGFR-1 / NRP-1 ; 

PubMed: 18790786     


HT29 cells were treated with oxaliplatin (0.2 and 2 μmol/L) in 1% MEM-FBS. Western blotting analysis showed that oxaliplatin treatment up-regulated VEGFR-1 and NRP-1 protein expression. 

p-AKT(Ser473) / AKT / PTEN / p-Src(Tyr416); 

PubMed: 18790786     


HT29 cells were treated with oxaliplatin for 5, 15, 30, and 60 min. Western blotting showed that oxaliplatin induced Akt activation, with peak phosphorylation occurring at 60 min and decreased PTEN. Phospho-Src increased at 30 min.

p-Src(Y418) / p-FAK(Y861) ; 

PubMed: 19383922     


Src and FAK activation by Western blots were determined at various time periods after oxaliplatin treatment (2.5 µM) for HT29 and KM12-L4 cells, and representative of triplicate experiments. Densitometry represents a ratio of the phosphorylated form to th䲧疝Ỵ疞㧀疜膉痘 瘿⟸෕ᾰƌ෕Ð 㺣痖帉痖Ѐ

18790786 19383922
Immunofluorescence
E-cadherin / Vimentin; 

PubMed: 30787271     


Silencing ATXN2L reversed oxaliplatin-induced epithelial mesenchymal transition in MGC803 cells.

ATXN2L / G3BP1; 

PubMed: 30787271     


Under different concentrations and durations of oxaliplatin stimulation, the immunfluorescence staining expressions of ATXN2L and G3BP1 were enhanced by different levels, and ATXN2L coexpressed with G3BP1 in stress granules. 

30787271
Growth inhibition assay
Cell viability ; 

PubMed: 28339092     


Cell viability curve of BGC-823 and MKN-28 cells treated with oxaliplatin at different concentrations. 

28339092
In vivo A weekly i.p. injection of Oxaliplatin at 10 mg/kg to nude mice bearing hepatocellular HCCLM3 tumors significantly reduces tumor volume and apoptotic index. [6] Oxaliplatin (5mg/kg, i.v. on days 1, 5 and 9) is active on T-leukemia-lymphoma L40 AKR with T/C of 1.77. Oxaliplatin is also efficient on intracerebrally grafted L1210 leukemia, MA 16-C xenografts, B16 melanoma xenografts, Lewis lung xenografts and C26 colon carcinoma xenografts. [7] Oxaliplatin induces impairment of retrograde neuronal transport in mice. [8]

Protocol

Cell Research:[4]
+ Expand
  • Cell lines: RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2 and HT-144 cell lines
  • Concentrations: ~100 μM
  • Incubation Time: 48 hours
  • Method: The cytotoxicity studies are carried out with the sulforhodamine-B microculture colorimetrie assay. Typically, cells are plated into 96-well plates on day 0 and exposed to Oxaliplatin on day 1; the sulforhodamine-B assay is carried out 48 h after Oxaliplatin exposure. The plates are incubated at 37 °C in 5% CO2 and 100% relative humidity at all times except when adding Oxaliplatin and during the final assay period. The initial number of cells plated for the assay ranged from 2-20 × 103 cells/50 /nL/well. The numbers of cells for plating and the drug exposure time are based on pilot studies using the criteria that (a) the cells in control wells are still in the log phase of growth on the day of the assay; (b) the maximum absorbance for the untreated controls on the day of the assay is in the range of 1.0 to 1.5; and (c) cells go through >2 doublings during the drug exposure. Eight wells are used per concentration. The plates are read at 570 and/or 540 nm using a Biotek Instruments model EL309 microplate reader interfaced with an IBM PC-compatible computer. The data are transferred and transformed into a LOTUS 1-2-3 format by the computer program DATALOG, and survival fractions are calculated by comparing the drug treated with control
    (Only for Reference)
Animal Research:[6]
+ Expand
  • Animal Models: Human hepatocellular carcinoma xenografts HCCLM3
  • Formulation: Water solution
  • Dosages: 10 mg/kg
  • Administration: A weekly i.p. injection
    (Only for Reference)

Solubility (25°C)

In vitro Water 3 mg/mL warmed (7.55 mM)
Ethanol 0.01 mg/mL (0.02 mM)
DMF Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% glucose (with warming)
For best results, use promptly after mixing.
3mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 397.29
Formula

C8H14N2O4Pt

CAS No. 61825-94-3
Storage powder
in solvent
Synonyms L-OHP

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04003792 Not yet recruiting Drug: oxaliplatin|Drug: FOLFIRI Protocol|Drug: Bevacizumab Liver Metastasis Colon Cancer Rabin Medical Center January 2020 Phase 2
NCT03872908 Not yet recruiting Device: Chilled gloves|Device: Surgical gloves Breast Cancer|Colorectal Cancer Centre Leon Berard June 15 2019 --

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Is it ok to dissolve Oxaliplatin in DMSO?

  • Answer:

    Even though cis-platin is soluble in DMSO, the use of DMSO to dissolve cis– or trans-diamminedichloroplatinum (DDP) in biological studies is strongly discouraged. The DMSO inserts itself into the ligand and inactivates platin-containing compounds. DMF is a much better choice than DMSO.

DNA/RNA Synthesis Signaling Pathway Map

Related DNA/RNA Synthesis Products

Tags: buy Oxaliplatin | Oxaliplatin supplier | purchase Oxaliplatin | Oxaliplatin cost | Oxaliplatin manufacturer | order Oxaliplatin | Oxaliplatin distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID